Global Blood Therapeutics Inc. (GBT)

50.24
1.86 3.84
NASDAQ : Health Technology
Prev Close 48.38
Open 48.09
Day Low/High 47.69 / 50.50
52 Wk Low/High 30.15 / 64.94
Volume 926.68K
Avg Volume 763.70K
Exchange NASDAQ
Shares Outstanding 60.23M
Market Cap 2.79B
EPS -3.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
GBT Reports Recent Business Progress And Third Quarter 2019 Financial Results

GBT Reports Recent Business Progress And Third Quarter 2019 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov.

GBT Announces Upcoming Data Presentations At 61st American Society Of Hematology Annual Meeting & Exposition

GBT Announces Upcoming Data Presentations At 61st American Society Of Hematology Annual Meeting & Exposition

Abstracts Include Three Post-hoc Analyses of Phase 3 HOPE Study Clinical Data Data Further Support the Safety and Efficacy of Voxelotor for Sickle Cell Disease (SCD) Examination of Real-world Evidence Further Establishes Relationship Between Higher Levels...

GBT Announces New Employment Inducement Grants

GBT Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Nov.

We Have a Market That Has Become a Little Extended

We Have a Market That Has Become a Little Extended

This looks like a normal pause within an uptrend.

GBT Announces Results Of Post-hoc Analysis Of Phase 3 HOPE Study Showing Improvement In Leg Ulcers In Patients With Sickle Cell Disease Treated With Voxelotor

GBT Announces Results Of Post-hoc Analysis Of Phase 3 HOPE Study Showing Improvement In Leg Ulcers In Patients With Sickle Cell Disease Treated With Voxelotor

First of Several Post-hoc Analyses Planned Using HOPE Study Clinical Data Findings Presented in Poster Session at 13 th Annual Academy for Sickle Cell and Thalassemia Conference SOUTH SAN FRANCISCO, Calif.

9 Stocks on My Radar Into Earnings

9 Stocks on My Radar Into Earnings

Don't be too quick to turn negative if there are some pullbacks.

There Are Signs of Improved Technical Action and Stock Picking

There Are Signs of Improved Technical Action and Stock Picking

China trade issue is no longer dominating the action.

GBT Announces New Employment Inducement Grants

GBT Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Oct.

GBT To Host Analyst & Investor Day On October 8 In New York

GBT To Host Analyst & Investor Day On October 8 In New York

SOUTH SAN FRANCISCO, Calif., Oct.

Sector Liquidations Provide Great Opportunity but Short Term Pain Is Tremendous

Sector Liquidations Provide Great Opportunity but Short Term Pain Is Tremendous

There is no respite today from the poor price action in individual stocks.

GBT Announces Participation At The 2019 Cantor Global Healthcare Conference

GBT Announces Participation At The 2019 Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept.

GBT Announces U.S. Food And Drug Administration Acceptance Of New Drug Application And Priority Review For Voxelotor For The Treatment Of Sickle Cell Disease

GBT Announces U.S. Food And Drug Administration Acceptance Of New Drug Application And Priority Review For Voxelotor For The Treatment Of Sickle Cell Disease

Priority Review Shortens FDA Review Time to Six Months from Standard 10 Months NDA Supported by Data from Phase 3 HOPE Study, which Demonstrated Statistically Significant and Sustained Improvements in Hemoglobin with Voxelotor SOUTH SAN FRANCISCO, Calif.

GBT Announces New Employment Inducement Grants

GBT Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Sept.

GBT Announces Participation At The 2019 Morgan Stanley Global Healthcare Conference

GBT Announces Participation At The 2019 Morgan Stanley Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept.

GBT And Sickle Cell Disease Association Of America To Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference

GBT And Sickle Cell Disease Association Of America To Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference

Patient Advocates, Healthcare Providers and Policy Makers to Discuss the Latest Advances and Future Trends for Treating Patients with SCD Conference Taking Place During National Sickle Cell Awareness Month Livestream of Conference will be Available...

GBT Reports Recent Business Progress And Second Quarter 2019 Financial Results

GBT Reports Recent Business Progress And Second Quarter 2019 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug.

GBT Announces Participation At The 2019 Wedbush PacGrow Healthcare Conference

GBT Announces Participation At The 2019 Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug.

GBT Announces New Employment Inducement Grants

GBT Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Aug.

GBT And Advocates Launch Disease Awareness Campaign Focused On Breaking Down Stigmas Associated With Sickle Cell Disease

GBT And Advocates Launch Disease Awareness Campaign Focused On Breaking Down Stigmas Associated With Sickle Cell Disease

Company Also Launches Disease Awareness Campaign to Raise Awareness Among Physicians About the Silent Damage Caused by Sickle Cell Disease

GBT Announces New Employment Inducement Grants

GBT Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., July 09, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc.

SS&C Increases Offer On Non-Binding Indicative Proposal To Acquire GBST Holdings Limited

SS&C Increases Offer On Non-Binding Indicative Proposal To Acquire GBST Holdings Limited

WINDSOR, Conn., July 3, 2019 /PRNewswire/ -- SS&C Technologies Holdings, Inc.

SS&C Enters Into Non-Binding Indicative Proposal To Acquire GBST Holdings Limited

SS&C Enters Into Non-Binding Indicative Proposal To Acquire GBST Holdings Limited

WINDSOR, Conn., July 1, 2019 /PRNewswire/ --  SS&C Technologies Holdings, Inc.

Notable Monday Option Activity: GBT, AKS, BOLD

Notable Monday Option Activity: GBT, AKS, BOLD

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Global Blood Therapeutics Inc , where a total of 4,413 contracts have traded so far, representing approximately 441,300 underlying shares. That amounts to about 51.3% of GBT's average daily trading volume over the past month of 859,935 shares.

Noteworthy Thursday Option Activity: GBT, AMBC, ANF

Noteworthy Thursday Option Activity: GBT, AMBC, ANF

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Global Blood Therapeutics Inc , where a total of 3,147 contracts have traded so far, representing approximately 314,700 underlying shares. That amounts to about 49.1% of GBT's average daily trading volume over the past month of 641,280 shares.

I Like These 2 Smaller Name Biotech Stocks

I Like These 2 Smaller Name Biotech Stocks

I still believe it will be a big year for buyouts across the biotech industry.

The Fed and Trump Are Both Wrong: Cramer's 'Mad Money' Recap (Tuesday 12/4/18)

The Fed and Trump Are Both Wrong: Cramer's 'Mad Money' Recap (Tuesday 12/4/18)

Markets looking for reassurance aren't getting any from the White House or the Federal Reserve, Jim Cramer says.

Interesting GBT Put And Call Options For June 2019

Interesting GBT Put And Call Options For June 2019

Investors in Global Blood Therapeutics Inc saw new options become available this week, for the June 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Global Blood Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Global Blood Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Global Blood Therapeutics, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Global Blood Therapeutics, Inc. - GBT

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Global Blood Therapeutics, Inc. - GBT

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Global Blood Therapeutics, Inc.